Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Guzmán Herrador, Bernardo R ^a,b   Aavitsland, Preben ^a   Feiring, Berit ^a   Riise Bergsaker, Marianne A ^a   Borgen, Katrine ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; ALPHA TOCOPHEROL; ASO3B ADJUVANT; IMMUNOLOGICAL ADJUVANT; POLYSORBATE; SQUALENE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; DRUG EFFICACY; HUMAN; IMMUNITY; INFANT; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; NORWAY; NORWEGIAN IMMUNISATION REGISTRY; NORWEGIAN SURVEILLANCE SYSTEM FOR COMMUNICABLE DISEASES; OUTCOME ASSESSMENT; PANDEMIC; POPULATION BASED CASE CONTROL STUDY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; VACCINE FAILURE; DRUG COMBINATION; FEMALE; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; NEWBORN; REGISTER; STATISTICS; TREATMENT OUTCOME; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NORWAY; POLYSORBATES; REGISTRIES; RETROSPECTIVE STUDIES; SQUALENE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860517105     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-63     Document Type: Article

References (18)

1. Folkehelseinstitutet Rapport om scenarier for pandemien og andre influensaepidemier i 2010-2011 (Norwegian Institute of Public Health: Report on scenarios for pandemic influenza and other influenza epidemics in 2010-2011) Norwegian Folkehelseinstitutet., http://www.fhi.no/dokumenter/3c807895b6.pdf
2. European Medicines Agency Pandemrix. Summary for the public European Medicines Agency., http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000832/human_med_000965.jsp&murl=menus/medicines/medicines.jsp&jsenabled=true
3. European Centre for Disease Prevention and Control The 2009 A(H1N1) pandemic in Europe. A review of the experience. Special report. Stockholm 2010, European Centre for Disease Prevention and Control.
4. Folkehelseinstituttet Faktahefte om vaksine mot pandemisk influenza. (Norwegian Institute of Public Health: Facts about vaccine against pandemic influenza.), Norwegian Folkehelseinstituttet., http://www.fhi.no/dav/f81e5aec12.pdf
5. Folkehelseinsitituttet Rapport om anbefalt rekkefølge for vaksinering mot ny influensa A(H1N1), 16. september 2009. (Norwegian Institute of Public Health: Report on the recommendations for vaccination against the new influenza A (H1N1), 16 September 2009), Norwegian Folkehelseinsitituttet., http://www.fhi.no/dokumenter/ec53d5ef4f.pdf
6. Folkehelseinsitituttet Rapport nummer to om vaksinasjon rekkefølge, versjon 2 23.10.2009. (Norwegian Institute of Public Health: Report number two on the vaccination recommendations, version 2 23.10.2009), Norwegian Folkehelseinsitituttet., http://www.fhi.no/dokumenter/f332d0ae39.pdf
7. Direktoratet for samfunnssikkerhet og beredskap Rapport. Ny influenza A(H1N1) 2009. Gjennomgang av erfaringene I Norge.; 2010. (Norwegian Directorate for Civil Protection and Emergency Planning: Report. New influenza A(H1N1) 2009. Review of the experiences in Norway; 2010.), Norwegian Direktoratet for samfunnssikkerhet og beredskap.
8. European Centre for Disease Prevention and Control Protocol for cohort database studies to measure influenza vaccine effectiveness in the European Union and European Economic Area Member States. Technical document 2009, European Centre for Disease Prevention and Control.
9. Valenciano M, Kissling E, Cohen J-M, Oroszi B, Barret A-S, Rizzo C, Nunes B, Pitigoi D, Larrauri Cámara A, Mosnier A, Horvath JK, O'Donnell J, Bella A, Guiomar R, Lupulescu E, Savulescu C, Ciancio B, Kramarz P, Moren A. Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009-2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-control Study. PLoS Med 2011, 8(1):e1000388. 10.1371/journal.pmed.1000388, 3019108, 21379316.
10. Emborg HD, Grove Krause T, Hviid A, Simonsen J, Mølbak K. Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. BMJ 2012, 344:d7901.
11. Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis J. Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines. PLoS ONE 2011, 6(9):e24384. 10.1371/journal.pone.0024384, 3167852, 21915319.
12. Osterholm M, Kelley N, Sommer A, Belongia E. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44. 10.1016/S1473-3099(11)70295-X, 22032844.
13. Hardelid P, Flemng D, McMenamin J, Andrews N, et al. Effectiveness of pandemic and seasonal influenza vaccines in preventing pandemic influenza A(H1N1) 2009 infection in England and Scotland 2009-2010. Euro Surveill 2011, 16(2). pii=19763.
14. Simpson CR, Ritchie LD, Robertson C, Sheikh A, et al. Effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine (Scotland). Health Technol Assess 2010, 14:313-346.
15. Wichmann O, Stöcker P, Poggensee G, Altmann D, et al. Pandemic Influenza A (H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 2010, 15(18):pii-1956.
16. Ortqvist T, Berggren I, de Jong B, Svenungsson B. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of Influenza A(H1N1)v, in Stockholm county, Sweden. Clin Infec Dis 2011, 52:1203-1211.
17. Van Buynder PG, Dhaliwai JK, Van Buynder JL, Minville-LeBlanc M, et al. Protective effect of single dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respir Viruses 2010, 4:171-178.
18. Mamelund SE, Storsæter J, Haugen IL, Ege MS, Bergsaker MA. Clinical efficiency after one dose of Pandemrix in Norway. BMJ Rapid Response 2009, , http://www.bmj.com/rapid-response/2011/11/02/clinical-efficiency-after-one-dose-pandemrix-norway